| Target Molecule | Thymosin Alpha-1 (Tα1) |
| Synonyms | Tα1, Thymosin α1, Thymalfasin, Zadaxin |
| CAS Number | 62304-98-7 (active ingredient thymalfasin also listed as 69440-99-9) |
| Sequence (3-Letter) | Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn-OH |
| Sequence (1-Letter) | Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN |
| Molecular Formula | C₁₂₉H₂₁₅N₃₃O₅₅ |
| Molecular Weight | 3108.3 |
| Service Category | Custom Peptide Synthesis / CDMO Manufacturing |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98% via HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Acetate (standard for clinical analogues), TFA, or custom salt options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with Precision N-Terminal Capping |
| Modification Options | N-terminal acetylation, stable isotope labeling (13C, 15N), fluorescent tags, deamidation standards |
| Available Scale | Milligram (R&D) to Kilogram (Commercial CDMO) |
| Analytical Data | Comprehensive COA, HPLC, MS, and capping confirmation provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, analytical development, and industrial formulation. Not a finished medicine. |
Thymosin Alpha-1 (CAS 62304-98-7) is a 28-amino acid immunomodulatory peptide carrying an N-terminal acetyl group (Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN). We target this sequence to supply high-purity reference materials, analytical standards, and raw materials for immunology, oncology, and infectious disease research.
We utilize optimized solid-phase peptide synthesis (SPPS) protocols on low-loading resins. Because the 28-residue chain contains multiple acidic residues (Asp, Glu) prone to aspartimide formation, our peptide synthesis platform applies specialized base cocktails and continuous monitoring, ensuring high-fidelity chain assembly and complete N-terminal capping.
Yes. We provide specialized peptide modification services for Thymosin Alpha-1. Options include site-specific stable isotope labeling (13C, 15N) for quantitative mass spectrometry (LC-MS/MS), fluorescent and biotin tagging, and the synthesis of unacetylated, deamidated, or beta-aspartyl reference standards for analytical method validation.
Our manufacturing infrastructure scales production from milligram-level analytical batches to multigram and kilogram commercial quantities. We optimize preparative HPLC purification and controlled counter-ion exchange (ensuring acetate salt conversion) to guarantee strict batch-to-batch consistency.
We operate as an integrated technical partner providing complete peptide CDMO solutions. Our team manages sequence optimization, impurity profiling, analytical method validation, and regulatory documentation to advance complex preclinical and commercial pipelines.
Thymosin Alpha-1 (Tα1, CAS 62304-98-7), identical in sequence to the active pharmaceutical ingredient thymalfasin, is a 28-amino acid peptide defined by the N-terminally acetylated sequence Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN. Operating as a crucial regulator of immune system signaling, it stimulates T-cell differentiation and maturation. Synpeptide provides comprehensive custom synthesis solutions for this molecule, showcasing our technical capabilities in long-chain assembly, capping chemistries, and CDMO manufacturing.
Constructing a 28-amino acid chain with multiple consecutive glutamic acid, aspartic acid, and lysine residues presents distinct chemical hurdles, notably aspartimide formation and chain aggregation. Our custom peptide synthesis platform resolves these hurdles using optimized Solid-Phase Peptide Synthesis (SPPS) protocols on low-loading resins. By deploying steric-hindrance-minimizing coupling reagents, temperature control, and complete N-terminal acetyl capping, we suppress truncated byproducts, delivering raw materials with rigorous purity specifications (typically ≥95% or ≥98% via HPLC).
The native bioactivity and serum half-life of Thymosin Alpha-1 depend strictly on complete N-terminal acetylation. Incomplete capping leaves unacetylated peptide, which represents a critical process-related impurity. Through our peptide modification services, we execute precise capping protocols and synthesize defined unacetylated, deamidated, or beta-aspartyl variants to serve as reference standards for stability-indicating analytical assays. We also provide stable isotope labeling (13C, 15N) and fluorescent conjugates for pharmacokinetic tracking.
Transitioning an immunomodulatory peptide from analytical scale to commercial volume demands robust chemical engineering during downstream processing. We execute large-scale peptide synthesis for Thymosin Alpha-1 by optimizing fluid dynamics and high-capacity preparative HPLC purification. Our facilities accommodate requirements from milligram research batches to kilogram commercial lots, ensuring uniform counter-ion exchange (consistently achieving the acetate salt form) and reproducible lyophilization profiles across all production volumes.
We deliver comprehensive technical support as a fully established peptide CDMO. Our development specialists assist pharmaceutical partners with process optimization, stability testing, impurity identification, and analytical method validation. Every batch is released with complete documentation—including COA, HPLC purity traces, and exact mass confirmation—ensuring regulatory alignment for downstream therapeutic programs.
